{"schema_version":"secwatch.filing_event.v1","accession":"0001630627-26-000017","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2026-08-07T11:10:15+00:00","discovered_at":"2026-08-07T11:15:04.195530+00:00","generated_at":"2026-08-07T11:15:19.394701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Treace Q2 2026 revenue $45.4M (-4% YoY), net loss $15.9M, raises FY guidance","bullets":["Q2 2026 revenue $45.4M vs $47.4M in Q2 2025 (-4%); net loss $(15.9)M or $(0.24)/share.","Adjusted EBITDA loss $(3.5)M, improved from $(3.6)M; gross margin 78.5% vs 79.7%.","Cash usage cut 57% YoY; cash and securities $45.6M at June 30, 2026.","FY 2026 revenue guidance raised to $204-212M (from $202-212M); EBITDA loss narrowed to $3-5M.","New products: SuperBite Screw System launched, HyperPlate XM first case; 40% of surgeons use new bunion systems."],"urls":{"canonical":"https://secwatch.observer/filing/0001630627-26-000017","json":"https://secwatch.observer/filing/0001630627-26-000017.json","markdown":"https://secwatch.observer/filing/0001630627-26-000017.md","text":"https://secwatch.observer/filing/0001630627-26-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000163062726000017/0001630627-26-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000163062726000017/tmci-20260807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-07T11:15:19.394701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}